The Global Landscape of Neuropsychiatric Genetics of Psychosis

Severe psychiatric conditions, including schizophrenia and bipolar disorder, affect millions of individuals globally and contribute substantially to long-term morbidity. Historically, major genomic discovery initiatives have recruited cohorts predominantly from high-income nations with European ancestry. Consequently, modern psychiatric genomics lacks sufficient ancestral diversity, leaving non-European populations significantly underrepresented in genetic studies. The field of neuropsychiatric genetics of psychosis specifically seeks to address these disparities by examining diverse, understudied populations. Because African ancestral genomes exhibit the greatest human genetic variation and shorter linkage disequilibrium blocks, their inclusion provides indispensable biological resolution. Researchers can leverage this unique genetic architecture to fine-map causal variants and pinpoint disease-associated loci with greater precision. Furthermore, expanding research beyond homogenous populations ensures that emerging polygenic risk scores yield equitable clinical utility worldwide. The NeuroGAP-Psychosis initiative represents a transformative case-control study conducted across Ethiopia, Kenya, South Africa, and Uganda. By enrolling over 42,000 participants, this landmark project establishes a critical foundation for global psychiatric genetics.

Cohort Overview and Demographic Distribution Across Sites

The NeuroGAP-Psychosis project successfully enrolled 42,953 participants between 2018 and 2023, comparing individuals living with psychotic disorders against population-matched controls. Overall, male participants constituted 57.3% of the total cohort, yet investigators observed substantial demographic differences across participating nations. For instance, Ethiopia recruited a cohort with 65.8% male representation, whereas Uganda enrolled 46.6% male participants. These demographic variations reflect distinct local healthcare-seeking behaviors, referral pathways, and regional socioeconomic factors that influence clinical presentations. In addition, recruitment teams engaged diverse healthcare settings, ranging from specialized tertiary psychiatric hospitals to primary outpatient clinics. To ensure rigorous ethical standards, investigators routinely administered the University of California Brief Assessment of Capacity to Consent tool. This standardized assessment verified that participants experiencing active psychiatric symptoms maintained adequate cognitive capacity to provide informed consent. Therefore, this comprehensive baseline cohort captures rich phenotypic diversity while maintaining high standards of bioethical governance across Eastern and Southern Africa.

Diagnostic Disparities in Schizophrenia and Bipolar Disorder

Across the enrolled psychiatric cases, clinical teams identified striking differences in primary diagnostic categories across the four nations. Specifically, schizophrenia or psychotic disorder not otherwise specified accounted for 75.5% of cases in Ethiopia, compared to 44.4% in Uganda. In contrast, bipolar disorder or mania not otherwise specified represented 53.9% of cases in Uganda, but only 24.0% in Ethiopia. These pronounced diagnostic variations underscore regional differences in psychiatric training, clinical documentation practices, and local nosological traditions. Furthermore, clinical diagnostic patterns often reflect the predominant symptom manifestations that prompt formal hospital admission within specific health systems. Because schizophrenia and bipolar disorder demonstrate high genetic correlation and shared biological pathways, rigid diagnostic boundaries frequently obscure overlapping clinical phenotypes. Consequently, these baseline epidemiological findings highlight the vital necessity of harmonizing diagnostic criteria during large-scale genetic analyses. Clinicians must recognize that diagnostic labels reflect interactions between neurobiology, provider judgment, and healthcare frameworks.

Comorbidity Profiles and Environmental Risk Factors

The NeuroGAP-Psychosis study comprehensively characterized medical comorbidities, substance use patterns, and traumatic life events across all participants. Notably, researchers identified significant differences in physical health conditions between psychiatric cases and control groups across all recruitment sites. Individuals diagnosed with severe psychotic disorders experienced elevated rates of cardiometabolic disturbances, nutritional challenges, and chronic infectious illnesses. In addition, substance use profiles varied markedly by country, reflecting distinct cultural traditions, regional availability, and regulatory environments. For example, local variations in khat consumption, tobacco use, alcohol intake, and cannabis exposure contributed to distinct clinical presentations. Furthermore, documented histories of severe psychosocial trauma and adverse life events were notably prevalent among psychiatric cases. These observational findings strongly reinforce the biopsychosocial model of severe mental disorders, wherein environmental insults intersect with genetic predispositions. Therefore, comprehensive clinical management must address physical comorbidities and environmental exposures alongside psychiatric pharmacotherapy.

Methodological and Cross-Cultural Challenges in Phenotyping

Executing large-scale psychiatric genomics across diverse multicultural populations introduces substantial methodological and logistical complexities. First, study teams had to translate and administer standardized assessment batteries across multiple indigenous and national languages. Rigorous translation and back-translation protocols were mandatory to ensure that complex psychological constructs retained conceptual and diagnostic fidelity. In addition, cultural variations in symptom reporting influenced phenotyping, as distress frequently presents through somatic idioms or unique spiritual explanations. Recruitment catchment areas also introduced notable heterogeneity, because urban university teaching hospitals captured different clinical severities than rural district facilities. Furthermore, differences in access to formal psychiatric services influenced the duration of untreated psychosis and symptom severity at enrollment. Consequently, analytical teams must implement advanced computational methods to account for site-specific covariates, environmental confounders, and phenotypic variance. Overcoming these cross-cultural phenotyping challenges is critical for eliminating spurious associations in genome-wide analyses.

Clinical Implications for Global Neuropsychiatric Practice

The baseline epidemiological and clinical insights from this landmark cohort provide valuable lessons for practicing clinicians worldwide. First, the observed cross-national variations demonstrate that psychiatric diagnostic categories remain dynamic constructs shaped by local institutional practices. Consequently, clinicians managing diverse patient populations must appreciate how cultural context and health systems influence psychiatric presentations and documentation. Furthermore, medical practitioners should routinely screen for cardiometabolic disorders and infectious comorbidities, given their high prevalence in individuals with psychosis. In addition, identifying unique environmental risk factors, such as regional substance use and traumatic exposures, enables targeted psychosocial interventions. From a therapeutic standpoint, incorporating ancestral genomic diversity into psychiatric discovery pipelines will eventually improve polygenic risk stratification and facilitate novel drug discovery. Thus, advancing global neuropsychiatric research directly supports the development of more personalized and equitable psychiatric care across international healthcare settings.

What is the primary objective of the NeuroGAP-Psychosis study?

The NeuroGAP-Psychosis study investigates genetic and environmental risk factors for psychotic disorders across sub-Saharan Africa. By recruiting over 42,000 participants in Ethiopia, Kenya, South Africa, and Uganda, the project expands global genomic diversity. Consequently, it aims to improve diagnostic precision and therapeutic discoveries for underrepresented populations worldwide.

Why did diagnostic proportions differ significantly across the participating countries?

Diagnostic proportions varied due to distinct regional healthcare systems, institutional referral pathways, and local diagnostic practices. Furthermore, cultural interpretations of psychiatric symptoms and differences in clinical catchment areas influenced diagnostic classifications. These factors caused notable variations in recorded rates of schizophrenia versus bipolar disorder across sites.

How does psychiatric genomic diversity benefit clinicians and patients globally?

Studying diverse populations enhances the fine-mapping of causal genetic variants shared across global ancestries. Furthermore, it prevents health disparities by ensuring polygenic risk prediction tools and targeted therapies function effectively across all demographic groups. Ultimately, this research fosters more equitable, accurate, and individualized psychiatric care worldwide.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Healthcare professionals should evaluate clinical decisions independently. Refer to the latest local and national guidelines for clinical practice.

References

1. Stroud RE et al. Demographic and clinical characteristics of participants in the Neuropsychiatric Genetics of African Populations-Psychosis (NeuroGAP-Psychosis) study: A descriptive analysis. PLoS One. 2026. doi: 10.1371/journal.pone.0356360. PMID: 42647474.


2. Stevenson A et al. Neuropsychiatric Genetics of African Populations-Psychosis (NeuroGAP-Psychosis): a case-control study protocol and GWAS in Ethiopia, Kenya, South Africa and Uganda. BMJ Open. 2019;9(2):e025469.